NM-2-AI

Norepinephrine release is the primary pharmacological action of NM-2-AI (inferred from 2-AI parent compound, Simmler 2014, Halberstadt 2019). Sympathomimetic blood pressure elevation in a patient with uncontrolled hypertension creates risk of hypertensive emergency, stroke, or cardiac event.

Individuals with structural heart disease, ischemic heart disease, heart failure, or arrhythmia disorders face amplified risk from NM-2-AI's sympathomimetic cardiovascular activation. The 82% predicted cardiovascular toxicity probability (in silico, Jurowski & Frydrych 2026) and one documented polydrug fatality further support this contraindication. Pre-existing cardiac pathology lowers the threshold for adverse cardiovascular events.

Individuals with epilepsy or other seizure disorders face increased seizure risk from NM-2-AI's stimulant pharmacology. Stimulant compounds as a class lower seizure threshold. This risk is further amplified by potential co-administration with tramadol (rated lethal interaction in seed data), which independently reduces seizure threshold.

Monoamine releasing agents can trigger manic or hypomanic episodes in individuals with bipolar disorder. NM-2-AI's stimulant pharmacology — primarily noradrenergic with possible secondary dopaminergic activity — poses this class-level risk.

Individuals with schizophrenia, schizoaffective disorder, or history of psychotic episodes face increased risk from stimulant compounds. NM-2-AI's inferred secondary dopaminergic activity and primary noradrenergic release may precipitate or exacerbate psychotic symptoms, particularly at high doses or with repeated administration.

NM-2-AI is metabolized hepatically via N-demethylation, hydroxylation, and NAT2-mediated acetylation (Manier et al. 2020, Mestria et al. 2021). Hepatic impairment would reduce clearance of both NM-2-AI and its pharmacologically active metabolite 2-AI, prolonging and intensifying effects. MDAI, a structural analog, shows strong cytotoxic potential in HepG2 hepatocyte cells exceeding MDMA (Richter et al. 2019), raising concern about direct hepatotoxicity in the aminoindane class.

NM-2-AI acts as a sympathomimetic vasoconstrictor through norepinephrine release. Sympathomimetic agents are contraindicated in pregnancy due to reduction of uterine blood flow, risk of fetal hypoxia, and potential teratogenic effects. No reproductive toxicity studies have been conducted for NM-2-AI or any aminoindane.

Concurrent use of any monoamine oxidase inhibitor (irreversible or reversible) with NM-2-AI is absolutely contraindicated. The mechanism of NM-2-AI as a monoamine releasing agent means MAOIs would prevent metabolic degradation of released norepinephrine and any released serotonin or dopamine, producing potentially fatal hypertensive crisis and/or serotonin syndrome. This contraindication is class-level for all monoamine releasing agents.